This episode reveals why the plant everyone talks about is not the one industry actually uses. The discussion contrasts T. iboga — with its low yield, slow growth, and conservation pressures — against Voacanga africana, which dominates the alkaloid trade due to high voacangine content. The strategic chemistry of converting voacangine to ibogaine via ester hydrolysis and decarboxylation is explained at the level of approach and significance. CITES status and Gabonese heritage controls are addressed, as is the sustainability argument for Voacanga. The episode closes with implications for impurity fingerprints and sourcing for future clinical programs.